Reaction
Heart Valve Replacement reporting signals
As of the last recalculation, Heart Valve Replacement appears in 1,447 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is RANOLAZINE (PRR 23.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranolazine | 17 | 23.7 | 23.7 |
| Bosentan | 43 | 12.6 | 12.6 |
| Tafamidis | 10 | 12.3 | 12.3 |
| Ambrisentan | 82 | 10.0 | 10.0 |
| Epoprostenol | 9 | 9.9 | 10.0 |
| Dronedarone | 7 | 9.9 | 9.9 |
| Macitentan | 40 | 8.5 | 8.5 |
| Selexipag | 15 | 8.4 | 8.4 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 9 | 7.8 | 7.8 |
| Patiromer | 7 | 7.3 | 7.3 |
| Vibegron | 4 | 7.2 | 7.2 |
| Ibrutinib | 36 | 6.5 | 6.6 |
| Risankizumab-Rzaa | 36 | 6.5 | 6.5 |
| Carbidopa And Levodopa | 19 | 5.8 | 5.8 |
| Nintedanib | 12 | 5.5 | 5.5 |
| Relugolix | 7 | 4.3 | 4.3 |
| Dabigatran Etexilate Mesylate | 21 | 4.2 | 4.2 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 3.9 | 3.9 |
| Evolocumab | 38 | 3.4 | 3.4 |
| Droxidopa | 3 | 2.0 | 2.0 |
| Cinacalcet Hydrochloride | 5 | 1.5 | 1.5 |